Effect of prostaglandin E₂ on urokinase‐type plasminogen activator production by human lung fibroblasts

References

• Wang D., DuBois R. N. Prostaglandins and cancer. Gut 2006; 55: 115–22
   PubMed Web of Science ®Google Scholar
• Hubbard W. C., Alley M. C., Gray G. N., Green K. C., McLemore T. L., Boyd M. R. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non‐small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res 1989; 49: 826–32
   PubMed Web of Science ®Google Scholar
• Tsuboi K., Sugimoto Y., Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002; 68‐9: 535–56
   Google Scholar
• Trompezinski S., Pernet I., Schmitt D., Viac J. UV radiation and prostaglandin E2 up‐regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res 2001; 50: 422–7
   PubMedGoogle Scholar
• Iwamoto J., Takahashi K., Mizokami Y., Otsubo T., Miura S., Narasaka T., et al. Expression of urokinase‐type plasminogen activator and its receptor in gastric fibroblasts and effects of nonsteroidal antiinflammatory drugs and prostaglandin. Dig Dis Sci 2001; 48: 2247–56
   Google Scholar
• Takahashi K., Uwabe Y., Sawasaki Y., Kiguchi T., Nakamura H., Kashiwabara K., et al. Increased secretion of urokinase‐type plasminogen activator by human lung microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 1998; 275: 47–54
   Google Scholar
• Duffy M. J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004; 10: 39–49
   PubMed Web of Science ®Google Scholar
• Andreasen P. A., Kjoller L., Christensen L., Duffy M. J. The urokinase‐type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1–22
   PubMed Web of Science ®Google Scholar
• Person M. D., Lo H. H., Towndrow K. M., Jia Z., Monks T. J., Lau S. S. Comparative identification of prostanoid inducible proteins by LC‐ESI‐MS/MS and MALDI‐TOF mass spectrometry. Chem Res Toxicol 2003; 16: 757–67
   PubMedGoogle Scholar
• Lee H. T. Protection against proximal tubule necrosis with 11‐deoxy‐16, 16‐dimethyl prostaglandin E2 in vitro. Am J Physiol Renal Physiol 2004; 287: 1111–12
   Google Scholar
• Jia Z., Person M. D., Dong J., Shen J., Hensley S. C., Stevens J. L., et al. Grp78 is essential for 11‐deoxy‐16,16‐dimethyl PGE2‐mediated cytoprotection in renal epithelial cells. Am J Physiol Renal Physiol 2004; 287: 1113–22
   PubMed Web of Science ®Google Scholar
• Han S. W., Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 2004; 314: 1093–9
   PubMed Web of Science ®Google Scholar
• Fiebich B. L., Schleicher S., Spleiss O., Czygan M., Hull M. Mechanisms of prostaglandin E2‐induced interleukin‐6 release in astrocytes: possible involvement of EP4‐like receptors, p38 mitogen‐activated protein kinase and protein kinase C. J Neurochem 2001; 79: 950–8
   PubMedGoogle Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–75
   PubMed Web of Science ®Google Scholar
• Takahashi K., Kiguchi T., Sawasaki Y., Karikusa F., Nemoto N., Matsuoka T., et al. Lung capillary endothelial cells produce and secrete urokinase‐type plasminogen activator. Am J Respir Cell Biol 1992; 7: 90–4
   PubMed Web of Science ®Google Scholar
• Duffy M. J. Urokinase‐type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem Soc Trans 2002; 30: 207–10
   PubMed Web of Science ®Google Scholar
• Degryse B., Sier C. F. M., Resnati M., Conese M., Blasi F. PAI‐1 inhibits urokinase‐induced chemotaxis by internalizing the urokinase receptor. FEBS Letters 2001; 505: 249–54
   PubMed Web of Science ®Google Scholar
• Croucher D., Saunders D. N., Ranson M. The urokinase/PAI‐2 complex: a new high affinity ligand for the endocytosis receptor LRP. J Biol Chem 2006; 281: 10206–13
   PubMedGoogle Scholar
• Yang L., Yamagata N., Yadav R., Brandon S., Courtney R. L., Morrow J. D., et al. Cancer‐associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003; 111: 727–35
   PubMed Web of Science ®Google Scholar
• Seno H., Oshima M., Ishikawa T., Oshima H., Takaku K., Chiba T., et al. Cyclooxygenase 2‐ and prostaglandin E2 receptor EP2‐dependent angiogenesis in ApcΔ716 mouse intestinal polyps. Cancer Res 2002; 62: 506–11
   PubMed Web of Science ®Google Scholar
• Sonoshida M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice. Nat Med 2001; 7: 1048–51
   PubMedGoogle Scholar
• Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., et al. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 2002; 62: 28–32
   PubMed Web of Science ®Google Scholar
• LeFever A., Funahashi A. Elevated prostaglandin E2 levels in bronchoalveolar lavage fluid of patients with bronchogenic carcinoma. Chest 1990; 98: 1397–402
   PubMedGoogle Scholar
• McLemore T. L., Hubbard W. C., Litterst C. L., Liu M. C., Miller S., McMahon N. A., et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 1988; 48: 3140–7
   PubMed Web of Science ®Google Scholar
• Dano K., Behrendt N., Hoyer‐Hansen G., Johnsen M., Lund L. R., Ploug M., et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676–81
   PubMed Web of Science ®Google Scholar
• Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface‐bound urokinase. J Cell Biol 1988; 107: 3437–45
   Google Scholar
• Quax P. H. A., Boxman L. A., Vankesteren C. A. M., Verheijen J. H., Ponec M. Plasminogen activators are involved in keratinocyte and fibroblast migration in wounded cultures in vitro. Fibrinolysis 1994; 8: 221–8
   Google Scholar
• Wilhelm O., Schmitt M., Hohl S., Senekowitsch R., Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296–302
   PubMed Web of Science ®Google Scholar